Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Benner

Showing results (301-310 of 347) with videos related to

Pageof 35
Sort By:
Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
European Urology Oncology|October 8, 2023
Digital Rectal Examination Is Not a Useful Screening Test for Prostate CancerAgne Krilaviciute, Nikolaus Becker, Jale Lakes, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Acta Neuropathologica|December 14, 2011
Biological and clinical heterogeneity of MYCN-amplified medulloblastomaAndrey Korshunov, Marc Remke, Marcel Kool, et al.
Nature Communications|November 16, 2018
Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancerNaveed Ishaque, Mohammed L Abba, Christine Hauser, et al.
Cancer Cell|April 13, 2016
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer PatientsNiels Halama, Inka Zoernig, Anna Berthel, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
European Urology|October 20, 2023
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE TrialMatthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al.
Pageof 35

Showing results (301-310 of 347) with videos related to

Sort By:
Pageof 35
Annals of Hematology|October 4, 2016
All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 studyRichard F Schlenk, Michael Lübbert, Axel Benner, et al.
European Urology|May 15, 2024
Risk-adjusted Screening for Prostate Cancer-Defining the Low-risk Group by Data from the PROBASE TrialAgne Krilaviciute, Rudolf Kaaks, Petra Seibold, et al.
European Urology Oncology|October 8, 2023
Digital Rectal Examination Is Not a Useful Screening Test for Prostate CancerAgne Krilaviciute, Nikolaus Becker, Jale Lakes, et al.
BMC Cancer|May 30, 2019
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myelomaHans Salwender, Uta Bertsch, Katja Weisel, et al.
Acta Neuropathologica|December 14, 2011
Biological and clinical heterogeneity of MYCN-amplified medulloblastomaAndrey Korshunov, Marc Remke, Marcel Kool, et al.
Nature Communications|November 16, 2018
Whole genome sequencing puts forward hypotheses on metastasis evolution and therapy in colorectal cancerNaveed Ishaque, Mohammed L Abba, Christine Hauser, et al.
Cancer Cell|April 13, 2016
Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer PatientsNiels Halama, Inka Zoernig, Anna Berthel, et al.
Leukemia|November 17, 2021
Publisher Correction: Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
Leukemia|July 21, 2020
Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of ageElias K Mai, Kaya Miah, Uta Bertsch, et al.
European Urology|October 20, 2023
Multiparametric Magnetic Resonance Imaging in Prostate Cancer Screening at the Age of 45 Years: Results from the First Screening Round of the PROBASE TrialMatthias Boschheidgen, Peter Albers, Heinz-Peter Schlemmer, et al.
Pageof 35